[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567048":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":14,"centralContacts":22,"locations":29,"responsibleParty":46,"collaborators":48,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":7,"studyType":64,"phases":7,"briefSummary":65,"conditions":66,"keywords":7,"overallStatus":32,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Haukeland University Hospital","OTHER",null,[9,12],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Blood samples for PK","Blood sampled for pharmacokinetic study",{"type":6,"name":10,"description":13,"armGroupLabels":7,"otherNames":7},"Blood samples before, shortly after infusion of already assigned\u002Fongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.",[15,18],{"name":16,"affiliation":5,"role":17},"Trond T. Serkland, M.D.","PRINCIPAL_INVESTIGATOR",{"name":19,"affiliation":20,"role":21},"Silje Skrede, M.D., PhD","University of Bergen","STUDY_DIRECTOR",[23,27],{"name":16,"role":24,"phone":25,"phoneExt":7,"email":26},"CONTACT","004755975563","trond.tretteberg.serkland@helse-bergen.no",{"name":19,"role":24,"phone":7,"phoneExt":7,"email":28},"silje.skrede@helse-bergen.no",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Haukeland University Hospital, Deparment of medical biochemistry and pharmacology","RECRUITING","Bergen","Vestland","5021","Norway","NO",{"type":39,"coordinates":40},"Point",[41,42],5.32415,60.39299,{"lat":42,"lon":41},[45],{"name":16,"role":24,"phone":25,"phoneExt":7,"email":26},{"type":47,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[49],{"name":20,"class":6},"100567048","rituximab-and-ocrelizumab-in-serum-with-multiple-sclerosis-100567048",false,"NCT06663111","Rituximab and Ocrelizumab in Serum With Multiple Sclerosis","Rituximab and Ocrelizumab in Serum With Multiple Sclerosis (ROS-MS)","ROS-MS","Inclusion Criteria:\n\n* Included in OVERLORD-MS (NCT04578639)\n* Willing to attend laboratory for blood sample collection at scheduled time points\n\nExclusion criteria:\n\n\\* Not willing to attend laboratory for blood sample collection at scheduled time points","ALL","18 Years","60 Years",{"count":62,"type":63},60,"ESTIMATED","OBSERVATIONAL","ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.",[67],"Relapsing Remitting Multiple Sclerosis","2024-10-28",{"date":70,"type":71},"2024-10-29","ACTUAL",{"date":73,"type":71},"2021-03-15",{"date":75,"type":63},"2027-12-31",{"name":5,"class":6},1]